High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$199K
$199,403
Total Sells (Filtered)
$7.6M
$7,630,054
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
EWTX
S
Edgewise Therapeutics, Inc.
Donovan Joanne M.
• Officer • CMO
10b5-1 SellΔOwn -74.9%
2026-04-01
$926,095
|
||||||
| EWTX |
Edgewise Therapeutics, Inc.
|
Officer • CMO
10b5-1 SellΔOwn -74.9%
|
2026-04-01 | $926,095 | S | Form 4 |
| EWTX |
Edgewise Therapeutics, Inc.
|
Officer • CMO
Other
|
2026-04-01 | $202,927 | M | Form 4 |
|
EWTX
S
Edgewise Therapeutics, Inc.
Donovan Joanne M.
• Officer • CMO
10b5-1 SellΔOwn -69.0%
2026-03-31
$685,308
|
||||||
| EWTX |
Edgewise Therapeutics, Inc.
|
Officer • CMO
10b5-1 SellΔOwn -69.0%
|
2026-03-31 | $685,308 | S | Form 4 |
| EWTX |
Edgewise Therapeutics, Inc.
|
Officer • CMO
Other
|
2026-03-31 | $151,073 | M | Form 4 |
|
EWTX
S
Edgewise Therapeutics, Inc.
Donovan Joanne M.
• Officer • CMO
10b5-1 SellΔOwn -37.1%
2026-03-27
$298,099
|
||||||
| EWTX |
Edgewise Therapeutics, Inc.
|
Officer • CMO
10b5-1 SellΔOwn -37.1%
|
2026-03-27 | $298,099 | S | Form 4 |
|
EWTX
S
Edgewise Therapeutics, Inc.
Donovan Joanne M.
• Officer • CMO
10b5-1 SellΔOwn -41.2%
2026-03-27
$208,635
|
||||||
| EWTX |
Edgewise Therapeutics, Inc.
|
Officer • CMO
10b5-1 SellΔOwn -41.2%
|
2026-03-27 | $208,635 | S | Form 4 |
|
EWTX
S
Edgewise Therapeutics, Inc.
Edris Badreddin
• Director
10b5-1 SellΔOwn -10.1%
2026-01-21
$403,034
|
||||||
| EWTX |
Edgewise Therapeutics, Inc.
|
Director
10b5-1 SellΔOwn -10.1%
|
2026-01-21 | $403,034 | S | Form 4 |
| EWTX |
Edgewise Therapeutics, Inc.
|
Director
10b5-1 Sell
|
2026-01-21 | $223,891 | S | Form 4 |
|
EWTX
S
Edgewise Therapeutics, Inc.
Edris Badreddin
• Director
10b5-1 SellΔOwn -10.8%
2026-01-21
$308,031
|
||||||
| EWTX |
Edgewise Therapeutics, Inc.
|
Director
10b5-1 SellΔOwn -10.8%
|
2026-01-21 | $308,031 | S | Form 4 |
|
EWTX
S
Edgewise Therapeutics, Inc.
Edris Badreddin
• Director
10b5-1 SellΔOwn -77.0%
2026-01-21
$1,957,083Large
|
||||||
| EWTX |
Edgewise Therapeutics, Inc.
|
Director
10b5-1 SellΔOwn -77.0%
|
2026-01-21 | $1,957,083Large | S | Form 4 |
|
EWTX
S
Edgewise Therapeutics, Inc.
Edris Badreddin
• Director
10b5-1 SellΔOwn -14.2%
2026-01-21
$507,428
|
||||||
| EWTX |
Edgewise Therapeutics, Inc.
|
Director
10b5-1 SellΔOwn -14.2%
|
2026-01-21 | $507,428 | S | Form 4 |
| EWTX |
Edgewise Therapeutics, Inc.
|
Director
Other
|
2026-01-21 | $5,339 | M | Form 4 |
| EWTX |
Edgewise Therapeutics, Inc.
|
Director
Other
|
2026-01-21 | $11,031 | M | Form 4 |
| EWTX |
Edgewise Therapeutics, Inc.
|
Director
Other
|
2026-01-21 | $20,194 | M | Form 4 |
| EWTX |
Edgewise Therapeutics, Inc.
|
Director
Other
|
2026-01-21 | $128,301 | M | Form 4 |
| EWTX |
Edgewise Therapeutics, Inc.
|
Director
Other
|
2026-01-21 | $5,400 | M | Form 4 |
|
EWTX
S
Edgewise Therapeutics, Inc.
Russell Alan J
• Officer • Chief Scientific Officer
Discretionary SellΔOwn -81.0%
2025-11-12
$2,112,450Large
|
||||||
| EWTX |
Edgewise Therapeutics, Inc.
|
Officer • Chief Scientific Officer
Discretionary SellΔOwn -81.0%
|
2025-11-12 | $2,112,450Large | S | Form 4 |
|
EWTX
M
Edgewise Therapeutics, Inc.
Russell Alan J
• Officer • Chief Scientific Officer
Other
2025-11-12
$18,000
|
||||||
| EWTX |
Edgewise Therapeutics, Inc.
|
Officer • Chief Scientific Officer
Other
|
2025-11-12 | $18,000 | M | Form 4 |
|
EWTX
P
Edgewise Therapeutics, Inc.
Fox Jonathan C
• Director
Discretionary BuyΔOwn +82.3%
2025-11-11
$199,403
|
||||||
| EWTX |
Edgewise Therapeutics, Inc.
|
Director
Discretionary BuyΔOwn +82.3%
|
2025-11-11 | $199,403 | P | Form 4 |